Posted by Michael Wonder on 03 Feb 2017
U.S. House panel to take up bill to spur generic drug development
2 February 2017 - A U.S. House of Representatives subcommittee will take up bipartisan legislation next week to foster generic drug development, the committee's chairman, Representative Greg Walden, said on Thursday.
"President (Donald) Trump made it clear ... he wants competition to lower drug prices, and that is precisely what this measure will help accomplish," Walden, a Republican from Oregon, said at a health subcommittee hearing.
"Specifically the bill will require FDA (the Food and Drug Administration) to prioritise, expedite and review generic applications of drug products that are currently in shortage, or where there are few manufacturers on the market," Walden said.
